Clearside Biomedical, Inc.
CLSD
$3.70
-$0.39-9.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.17M | 3.76M | 1.66M | 7.70M | 7.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.17M | 3.76M | 1.66M | 7.70M | 7.52M |
| Cost of Revenue | 397.00K | 397.00K | 149.00K | 0.00 | 142.00K |
| Gross Profit | 3.77M | 3.37M | 1.52M | 7.70M | 7.38M |
| SG&A Expenses | 11.21M | 11.81M | 11.81M | 11.69M | 11.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.02M | 29.64M | 30.55M | 32.35M | 33.29M |
| Operating Income | -21.86M | -25.88M | -28.88M | -24.65M | -25.77M |
| Income Before Tax | -27.00M | -30.10M | -34.35M | -31.88M | -33.46M |
| Income Tax Expenses | 715.00K | 715.00K | -- | -- | -- |
| Earnings from Continuing Operations | -27.71 | -30.81 | -34.35 | -31.88 | -33.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.71M | -30.81M | -34.35M | -31.88M | -33.46M |
| EBIT | -21.86M | -25.88M | -28.88M | -24.65M | -25.77M |
| EBITDA | -21.53M | -25.60M | -28.66M | -24.48M | -25.66M |
| EPS Basic | -5.46 | -6.12 | -7.04 | -6.75 | -7.45 |
| Normalized Basic EPS | -3.32 | -3.74 | -4.40 | -4.22 | -4.66 |
| EPS Diluted | -5.46 | -6.12 | -7.04 | -6.75 | -7.45 |
| Normalized Diluted EPS | -3.32 | -3.74 | -4.40 | -4.22 | -4.66 |
| Average Basic Shares Outstanding | 20.36M | 20.15M | 19.68M | 18.78M | 17.93M |
| Average Diluted Shares Outstanding | 20.36M | 20.15M | 19.68M | 18.78M | 17.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |